

Exploring the Relationship Between Opioid Use Disorder and Major Depressive Disorder: A Case Study from Kentucky

Dr. MD Rakibul Hasan*

Department of Health Promotion and Behavioural Sciences, University of Louisville, United States of America.

Volume 8 Issue 4, 2024

Article Information

Received date: 04/11/2024

Published date: 20/11/2024

***Corresponding author**

*Dr. Md. Rakibul Hasan, Department of Mathematics, Hajee Mohammad Danesh Science and Technology University, Dinajpur-5200, Bangladesh.

***Key Words:**

Opioid use disorder, Depression, MDD, cognitive function, drug, Case report, Kentucky, USA

Abstract

This case study explores the intricate and interconnected problems of drug usage and mental health in Kentucky, a state that has been greatly affected by the opioid epidemic and the high rate of mental illness. The study draws attention to the many difficulties that people with multiple diagnoses encounter, including as stigma, difficulty obtaining integrated treatment, and the need for extensive support networks. Through a thorough case study of a 35-year-old male patient from Louisville, Kentucky, who has been struggling with severe depressive disorder and opioid use disorder, the paper emphasizes how crucial integrated therapy methods are. By combining medication-assisted treatment (MAT), cognitive-behavioral therapy (CBT), and community support, the patient's path from many unsuccessful rehabilitation efforts to notable progress is painstakingly chronicled. In treating drug use and mental health difficulties, the case study demonstrates the efficacy of creative alternatives including peer support groups, telemedicine services, and community-based therapies. In order to improve outcomes for people with dual diagnoses throughout the United States, the paper ends with suggestions for expanding integrated care models and a discussion of the wider implications for public health policy.

Objective: The aim of this case report is to conduct a comprehensive case study that explores the relationship between opioid use disorder (OUD) and major depressive disorder (MDD). The study will emphasize the advantages and disadvantages of integrated treatment approaches in enhancing patient outcomes.

Introduction

Opioid use disorder (OUD) and major depressive disorder (MDD) are substantial public health concerns, particularly in Kentucky. Opioids, which are also referred to as narcotics, encompass both prescription pain relievers, such as hydrocodone and oxycodone, and illicit substances, such as heroin. (Phillips et al., 2017) These substances function by binding to opioid receptors in the brain, thereby reducing the perception of pain and generating euphoria. However, this can result in addiction and misuse. (Holton et al., 2018) Opioids are classified into three primary categories: natural (e.g., codeine, morphine), semi-synthetic (e.g., hydrocodone, oxycodone), and synthetic (e.g., methadone, fentanyl) (Trescot et al., 2008).

Major depressive disorder (MDD), also referred to as clinical depression, is a mental health condition that is widespread and is defined by a protracted period of profound sadness and a clear lack of interest in activities that were previously enjoyable. (Paykel, 2008) Many aspects of an individual's life are significantly affected by this disorder, such as their emotional responses, daily routines, and cognitive processes. The capacity of individuals with MDD to engage in social activities, maintain relationships, and function at work is frequently disrupted. (Kupferberg et al., 2016) The Beck Depression Inventory (BDI) and the Patient Health Questionnaire-9 (PHQ-9) are standardized assessment instruments that

healthcare providers employ to accurately diagnose MDD (Mitchell et al., 2016). Providing a structured approach to identifying and understanding the extent of the disorder, these instruments are intended to systematically assess the severity and presence of depressive symptoms. By conducting these evaluations, clinicians can create personalized treatment plans that cater to the unique requirements of individuals with MDD.(Behera et al., 2017)

The opioid crisis has had a substantial impact on Kentucky. In 2022, the state reported 2,135 overdose deaths, with opioids accounting for 81% of the fatalities. (<https://www.addictiongroup.org/kentucky/drug-statistics/>). Fentanyl, a synthetic opioid that is highly potent, was implicated in 72.5% of these fatalities. (<https://www.cdc.gov/nchs/products/databriefs/db491.htm>) Furthermore, Kentucky has a high incidence of mental health disorders. Approximately 23.77% of adults in Kentucky have experienced a mental illness in the past year, with a substantial proportion of them suffering from severe depressive disorder. (<https://www.cdc.gov/mmwr/volumes/72/wr/mm7224a1.htm>) Kentucky is a critical region for the research and resolution of these issues due to its high prevalence of opioid-related overdose fatalities and mental health disorders.(Thompson et al., 2023) The impact of these disorders is further exacerbated by the state's distinctive challenges, which include high poverty rates and limited access to healthcare. The objective of this case report is to emphasize the efficacy of strategies and interventions that can be implemented in comparable regions that are encountering these dual public health crises by concentrating on Kentucky. The compounded effects on the health and well-being of individuals make it imperative to address the co-occurrence of opioid use disorder and major depressive disorder. Integrated treatment approaches are necessary to effectively manage dual diagnoses, which are characterized by the presence of both a substance use disorder and a mental health disorder (Schuckit, 2006). This is of particular significance in Kentucky, where the opioid crisis and mental health issues are prevalent.

Case Presentation

Patient Profile: The patient is a 35-year-old male who resides in Louisville, Kentucky. He has a documented history of major depressive disorder (MDD) and opioid use disorder (OUD). His biography encompasses a decade-long battle with substance addiction, predominantly narcotics, and a concurrent diagnosis of depression.

History: The patient's struggle with substance misuse commenced in his early twenties, with prescription narcotics used as a result of a work-related injury. His consumption of heroin and other illicit opioids increased over time. He endured recurrent relapses in spite of numerous rehabilitation endeavors, including inpatient and

outpatient programs. His persistent feelings of melancholy, anhedonia (loss of interest in previously relished activities), and episodes of suicidal ideation have been characterized by his major depressive disorder, which was diagnosed at the same time as his substance use issues. His substance use has frequently been exacerbated by these depressive symptoms, resulting in a pernicious cycle of addiction and mental health deterioration.

Symptoms: The patient manifested severe symptoms of depression upon admission, such as profound melancholy, social withdrawal, and a lack of motivation. In the past year, he revealed that he had experienced numerous non-fatal overdoses as a result of his daily opioid use. Physical symptoms encompassed indicators of opioid dependence, including tolerance, withdrawal symptoms, and an obsession with the acquisition and utilization of opioids. Significant depressive symptoms, such as insomnia, feelings of worthlessness, and recurrent images of mortality, were identified during his mental health assessment. His capacity to engage in social relationships, maintain employment, and function in daily life was significantly impaired by the combination of these symptoms.

(https://www.naadac.org/assets/2416/2019NWRC_K_Michelle_Peavy_PowerPoint.pdf)

Intervention

Initial Treatment: The patient was committed to a residential treatment facility that specializes in the treatment of individuals with co-occurring disorders. During the initial phase of treatment, the primary objective was to safely manage withdrawal symptoms and stabilize the patient through detoxification. This phase encompassed medical supervision and support to guarantee that the patient's physical and mental health requirements were satisfactorily addressed during the detoxification process.

Integrated Care Approach: The comprehensive treatment plan was developed to simultaneously address the opioid use disorder and major depressive disorder through a multifaceted approach:

Medication-Assisted Treatment (MAT): Buprenorphine, a medication that alleviates opioid cravings and withdrawal symptoms, was prescribed to the patient.(Darke and Farrell, 2016) Buprenorphine functions by partially activating opioid receptors in the brain, which alleviates withdrawal symptoms and reduces cravings without generating the same level of euphoria as other opioids.(Committee on Medication-Assisted Treatment for Opioid Use Disorder, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine, 2019) This medication was a component of a more comprehensive approach to the patient's opioid

dependence and to facilitate long-term recovery.

Cognitive behavioral therapy (CBT): The patient engaged in consistent CBT sessions with the objective of addressing depressive symptoms and establishing effective coping mechanisms. CBT is a structured, time-limited therapy that emphasizes the identification and modification of negative thought patterns and behaviors.(Beck, 2020) The patient acquired the ability to manage symptoms of depression, cultivate healthier thought processes, and cultivate the ability to manage stress and substance use triggers through cognitive behavioral therapy (CBT).(Nakao et al., 2021)

Group Therapy: The patient participated in group therapy sessions, which offered a supportive environment for the exchange of experiences and the acquisition of insights from peers who were confronted with comparable obstacles. Group therapy is essential for individuals who are rehabilitating from substance use disorders and mental health issues, as it fosters a sense of community and belonging.(Ford et al., 2009) The patient was also afforded the opportunity to exercise social skills and receive feedback from others during these sessions.

Community Support: The treatment plan incorporated the patient's access to local resources, acknowledging the significance of a robust support network. This necessitated involvement in peer support organizations, which provide continuous accountability and motivation. Furthermore, the patient was enlisted in vocational training programs to enhance their job readiness.(Center for Substance Abuse Treatment, 1997)

Outcome

Short-term Progress: The patient's drug usage and mental health symptoms significantly improved within the first three months of comprehensive therapy. Regular drug tests that revealed no evidence of opioid usage corroborated his assertion of a discernible decrease in opiate cravings. (Center for Substance Abuse Treatment, 2012) His attitude, energy levels, and general perspective on life also improved, and his depressed symptoms started to lessen. The patient started to create better coping strategies for stress and emotional control and actively engaged in both individual and group treatment sessions.

Long-term Follow-up: The patient was still showing encouraging results at the six-month mark. He continued to attend regular treatment sessions and was clean, with no relapses noted. Additionally, the patient had obtained a part-time job, which was essential to his recuperation since it gave him a feeling of direction and regularity. He was able to restore his social network and sense of self-worth thanks to this job opportunity, which further aided in his mental health rehabilitation. The patient said that he felt more

optimistic about the future and that he was determined to keep up his sobriety and mental health. His improvement was maintained in large part by regular follow-ups and assistance from local resources.

Discussion

This case highlights numerous substantial obstacles associated with the treatment of individuals who have co-occurring opioid use disorder (OUD) and major depressive disorder (MDD). The pervasive stigma associated with both mental health issues and substance use disorders is one of the primary barriers.(Zwick et al., 2020) This stigma frequently serves as an impediment to individuals seeking assistance, as they are apprehensive about being judged or discriminated against.(Cheetham et al., 2022) Furthermore, there is a significant deficiency in access to integrated care, which involves the concurrent treatment of both conditions. Numerous treatment facilities are inadequately outfitted to manage dual diagnoses, which can result in fragmented care that impedes recovery.(Padwa et al., 2015) The treatment process is further complicated by the absence of comprehensive support systems, which include family, community, and healthcare providers.(Priester et al., 2016)

Innovative solutions are essential for surmounting these obstacles. Integrated care models that simultaneously address substance use and mental health issues have demonstrated potential to enhance patient outcomes. These models entail the collaborative efforts of primary care providers, addiction specialists, and mental health professionals to develop a comprehensive treatment plan. (McGinty and Daumit, 2020) Additionally, community-based interventions are essential. Programs that provide accommodation assistance, vocational training, and peer support can offer the requisite support for individuals to sustain their recovery.(Killaspy et al., 2022) Policy support is equally critical, as it can facilitate the implementation of integrated care models and guarantee that resources are allocated to support comprehensive treatment programs. (Harvey et al., 2023)

This case has substantial broader implications. The potential for the application of comparable strategies in other regions with high rates of OUD and MDD is underscored by the success of the integrated treatment approach in this case study.(Wiss, 2019) This case bolsters the argument for the widespread adoption of integrated treatment models by illustrating the efficacy of comprehensive, coordinated care. It also emphasizes the necessity of continuous research and policy development to address the intricate requirements of individuals with dual diagnoses. Reducing the burden of opioid addiction and mental health disorders in communities throughout the United States could be achieved by scaling these approaches, which could result in improved outcomes on a significantly larger scale.

In brief, this case study demonstrates the critical significance of integrating care to address both opioid use disorder and major depressive disorder. We can improve the quality of care and support long-term recovery for individuals who are facing these dual challenges by overcoming stigma, increasing access to comprehensive support systems, and implementing innovative solutions. (National Academies of Sciences et al., 2016) The lessons acquired from this case can be used to inform future endeavors to develop and refine treatment strategies, thereby guaranteeing that a greater number of individuals receive the comprehensive care necessary to achieve and sustain recovery.

Limitations:

The scope of this case report is limited by its emphasis on a singular patient, which may not be indicative of the general population. The generalizability and long-term applicability of the findings are also limited by the relatively brief follow-up period and the reliance on self-reported data.

Recommendations:

To enhance the management of co-occurring OUD and MDD, it is recommended that invested in integrated treatment facilities, enhanced access to mental health services, support community-based programs, and develop policies that promote comprehensive care models be implemented. In order to more effectively comprehend and resolve the intricacies of dual diagnoses, it is imperative to conduct ongoing research.

Conclusion

In summary, this case study illustrates that patients with major depressive disorder and opioid use disorder can experience substantial improvements in their outcomes when they receive integrated treatment. Patients can achieve improved overall health and stability by concurrently treating both conditions through coordinated treatment programs. The results emphasize the necessity of ongoing investment in integrated treatment facilities, expanded access to mental health services, and comprehensive community support programs. In regions such as Kentucky, which are significantly affected by these challenges, these measures are crucial for effectively addressing the interconnected crises of substance addiction and mental health issues. We can improve the quality of care and facilitate long-term recovery for individuals who are confronted with these dual challenges by implementing innovative and comprehensive strategies.

References

1. Beck JS (2020) Cognitive Behavior Therapy: Basics and Beyond. : Guilford Publications. Behera P, Gupta SK, Nongkynrih B, Kant S, Mishra AK and Sharan P (2017) Screening instruments for assessment of depression. *Indian Journal of Medical Specialities* 8(1): 31–37.
2. Center for Substance Abuse Treatment (2012) Managing chronic pain in adults with or in recovery from substance use disorders. Center for Substance Abuse Treatment (1997) A guide to substance abuse services for primary care clinicians.
3. Cheetham A, Picco L, Barnett A, Lubman DI and Nielsen S (2022) The impact of stigma on people with opioid use disorder, opioid treatment, and policy. *Substance Abuse and Rehabilitation*: 1–12.
4. Committee on Medication-Assisted Treatment for Opioid Use Disorder, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine (2019) Medications for opioid use disorder save lives.
5. Darke S and Farrell M (2016) Which medications are suitable for agonist drug maintenance? *Addiction* 111(5): 767–774.
6. Ford JD, FalLOT RD and Harris M (2009) Group therapy. *Treating Complex Traumatic Stress Disorders: An Evidence-Based Guide*: 415–440.
7. Harvey C, Zirnsak T, Brasier C, Ennals P, Fletcher J, Hamilton B, et al. (2023) Community-based models of care facilitating the recovery of people living with persistent and complex mental health needs: a systematic review and narrative synthesis. *Frontiers in Psychiatry* 14: 1259944.
8. Holton D, White E and McCarty D (2018) Public health policy strategies to address the opioid epidemic. *Clinical Pharmacology & Therapeutics* 103(6): 959–962.
9. Killaspy H, Harvey C, Brasier C, Brophy L, Ennals P, Fletcher J, et al. (2022) Community-based social interventions for people with severe mental illness: a systematic review and narrative synthesis of recent evidence. *World Psychiatry* 21(1): 96–123.
10. Kupferberg A, Bicks L and Hasler G (2016) Social functioning in major depressive disorder. *Neuroscience & Biobehavioral Reviews* 69: 313–332.
11. McGinty EE and Daumit GL (2020) Integrating mental health and addiction treatment into general medical care: the role of policy. *Psychiatric Services* 71(11): 1163–1169.
12. Mitchell AJ, Yadegarfar M, Gill J and Stubbs B (2016) Case finding and screening clinical utility of the Patient Health Questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies. *BJPsych Open* 2(2): 127–138.
13. Nakao M, Shiotsuki K and Sugaya N (2021) Cognitive-behavioral therapy for management of mental health and stress-related disorders: Recent advances in techniques and technologies. *BioPsychoSocial Medicine* 15(1): 16.
14. National Academies of Sciences, Division of Behavioral, Social Sciences, Board on Behavioral, Sensory Sciences and Committee on the Science of Changing Behavioral Health Social Norms (2016) Ending Discrimination Against People with Mental and Substance use Disorders: The Evidence for Stigma Change. : National Academies Press.
15. Padwa H, Guerrero EG, Braslow JT and Fenwick KM (2015) Barriers to serving clients with co-occurring disorders in a transformed mental health system. *Psychiatric Services* 66(5): 547–550.
16. Paykel ES (2008) Basic concepts of depression. *Dialogues in Clinical Neuroscience* 10(3): 279–289.
17. Phillips JK, Ford MA, Bonnie RJ and National Academies of Sciences, Engineering, and Medicine (2017) Evidence on strategies for addressing the opioid epidemic. In: Anonymous Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits

and Risks of Prescription Opioid Use. : National Academies Press (US).

18. Priester MA, Browne T, Iachini A, Clone S, DeHart D and Seay KD (2016) Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review. *Journal of Substance Abuse Treatment* 61: 47–59.
19. Schuckit MA (2006) Comorbidity between substance use disorders and psychiatric conditions. *Addiction* 101: 76–88.
20. Thompson K, Barocas JA, Delcher C, Bae J, Hammerslag L, Wang J, et al. (2023) The prevalence of opioid use disorder in Kentucky's counties: a two-year multi-sample capture-recapture analysis. *Drug and Alcohol Dependence* 242: 109710.
21. Trescot AM, Datta S, Lee M and Hansen H (2008) Opioid pharmacology. *Pain Physician* 11(2S): S133.
22. Wiss DA (2019) A biopsychosocial overview of the opioid crisis: Considering nutrition and gastrointestinal health. *Frontiers in Public Health* 7: 193.
23. Zwick J, Applese H and Arndt S (2020) Stigma: how it affects the substance use disorder patient. *Substance Abuse Treatment, Prevention, and Policy* 15: 1–4.